ARIAN CANCER

by Sarah Botting-Provost, MSc **Division of Cancer Epidemiology** McGill University August 2023





In Canada, approximately 3000 women will be diagnosed with ovarian cancer and 1950 are expected to die of the disease this year.

Ovarian cancer is the deadliest gynecological cancer, largely because:

- there is currently no reliable screening test
- signs and symptoms are not specific
- it is usually diagnosed at an advanced stage

Cancer can form in three different types of cells within the ovary:

- 1. Epithelial cells are the cells that cover the ovary: site of approximately 90% of ovarian cancers
- 2. Germ cells are inside the ovary: site of 5-10% of ovarian cancers
- 3. Stromal cells are the structural cells of the ovary: site of less than 5% of ovarian cancers

Risk factors for ovarian cancer include:



As we age, our cells are more likely to acquire damage, or genetic mutations, which increase the risk of cancer.



A family history of breast, ovarian, prostate, pancreatic, endometrial or colorectal cancer can indicate a higher risk for ovarian cancer.



Those who have endometriosis have nearly a 50% increased risk of ovarian cancer relative to other women.



Application of talc powder near the genital area has been linked to ovarian cancer.



Hereditary genetic mutations to the BRCA1 and BRCA2 genes can increase the risk of ovarian cancer by up to 50%. Those of Ashkenazi Jewish or French-Canadian heritage are more likely to carry this mutation.

Protective factor:



Oral contraceptive use has been shown to reduce the risk of ovarian cancer by 30-50%, EVEN reducing the risk in women who carry the BRCA1/2 mutation.

Treatment: Ovarian cancer is often treated using a combination of surgery, chemotherapy, and/or radiotherapy. The pandemic-related delays along the cancer treatment continuum only emphasize the importance of diagnosing and treating ovarian cancer early to allow prompt action.

Talk to your doctor if:

- You have a family history that puts you at an increased risk of ovarian cancer. You may be eligible to be tested for the BRCA1/2 mutation.
- You notice new and persistent or frequent symptoms such as bloating, fatigue, abdominal pain or discomfort, urinary symptoms, changes in bowel habits, difficulty eating, unexplained weight change, and/or menstrual irregularities.

an R. Brenner, Alabey Pairier, et al.: for the Canadian Cancer Statistics Advisory Committee. Projected estimates of cancer in Canada in 2022. CMAJ May 02, 2022 194 (17) E601-E607; doi: 10.1503/cmaj.212097

Loanse in Eventure, Mobely Profits, et al., for the Loansain Loader Statistics Advastry Committee Projected estimates of concer in Compania 2022. LPM 1979 UZ, 2022 M 4 (i) 12:00-to-2014 https://www.concer.gov/lobout-concer/course-prevention/risk/hermones/ord-centraceptives-fact-sheet#—text=0-varian*20cancer/catas*3.X/20Wmemit\(\)2004 below \(\)2005 20 https://www.concer.gov/lobout-concer/course-prevention/risk/hermones/ord-centraceptives-fact-sheet#—text=0-varian*20cancer\(\)3.X/20V 2005 \(\)3.X/20V 2005 \(